contract_awardAwarded Wednesday, May 27, 2026Analyzed

USANTIBIOTICS LLC: $30.0M Department of Health and Human Services Contract

Neutral

Summary

A $30.0M delivery order for amoxicillin capsules was awarded to privately-held USANTIBIOTICS LLC by HHS/ASPR. Because the recipient is private, no public tickers are directly affected, but the contract signals continued government investment in antibiotic stockpiling for pandemic preparedness.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.Private company USANTIBIOTICS LLC received $30M for amoxicillin capsules, no public ticker exposure.
  • 2.The award signals ongoing government stockpiling of generic antibiotics, supporting the healthcare sector's preparedness subsector.
  • 3.No direct legislative authorizing bill identified; likely funded through HHS/ASPR base appropriations for the Strategic National Stockpile.

Market Implications

No immediate market impact because the recipient is private. The contract is small relative to the generic drug market. For context, the U.S. generic antibiotic market is worth billions annually, and a $30M order is negligible for large players. No stock price movement is expected from this award alone.

Full Analysis

  1. This contract is a $30.0M delivery order to USANTIBIOTICS LLC for amoxicillin trihydrate oral capsules (500mg, 60- and 100-count), awarded by the Department of Health and Human Services through the Office of Assistant Secretary for Preparedness and Response. It runs from May 2026 to May 2027, indicating a one-year supply arrangement for a critical generic antibiotic. 2) USANTIBIOTICS LLC is not a publicly-traded entity or a recognized subsidiary of any public company. As a private firm, its financials and competitive position are opaque to public market investors. No tickers are mapped. 3) Related legislation includes S4551 (Restoring Overtime Pay Act of 2026, bearish, impact 2/10 on Healthcare), S4587 (Dietary Supplements Access Act, bullish, impact 3/10 on Healthcare), and S4634 (CONNECT Act, neutral, impact 2/10 on Healthcare). None of these bills directly authorize antibiotic procurement; the contract likely stems from BARDA or ASPR's Strategic National Stockpile (SNS) funding. 4) No publicly-traded subcontractors or suppliers are identified. Downstream beneficiaries could include generic drug manufacturers (e.g., $TEVA, $MYL) if they supply active pharmaceutical ingredients, but this is speculative. 5) Generic antibiotic contracts like this are routine SNS replenishments, typically stable and low-margin. They do not drive significant stock performance for large-cap pharma, but they reinforce the U.S. government's role as a reliable bulk buyer for essential medicines.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

proclamationJul 13, 2026

Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security

President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).

Exec OrderJun 25, 2026

Advancing Regenerative Agriculture and Strengthening American Farm Resilience

This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Contract Details

Recipient

USANTIBIOTICS LLC

Award Amount

$29,998,678

Awarding Agency

Department of Health and Human Services

Sub-Agency

Office of Assistant Secretary for Preparedness and Response

Contract Type

DELIVERY ORDER

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →